The National Institute for Health and Care Excellence (NICE) has published guidance recommending infliximab for use within its marketing authorisation as an option for treating severe active ankylosing spondylitis (AS) in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs.1
NICE last reviewed infliximab for AS in 2008 and decided that it was not cost-effective.2 However, the recent availability of biosimilar infliximab medicines in the UK has enabled NICE to recommend infliximab in its latest guidance for treating severe active AS "if treatment is started with the least expensive infliximab product".
